title: Pharmacoeconomics in HP-related diseases: more questions than answers.
authors.affiliation: University Hospital Brugmann ULB/VUB, B-Brussels.
authors.forename: M
authors.initials: M
authors.lastname: Deltenre
authors.forename: I
authors.initials: I
authors.lastname: De Bruyne
authors.forename: C
authors.initials: C
authors.lastname: Jonas
authors.forename: E
authors.initials: E
authors.lastname: De Koster
mesh_terms: D000897:Anti-Ulcer Agents / Q000191:economics* / Q000627:therapeutic use; D017281:Cost of Illness; D003365:Costs and Cost Analysis; D017850:Economics, Pharmaceutical / Q000706:statistics & numerical data; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy* / Q000191:economics; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D018803:Models, Economic; D009853:Omeprazole / Q000191:economics / Q000627:therapeutic use; D011899:Ranitidine / Q000191:economics / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000209:etiology / Q000517:prevention & control; D013276:Stomach Ulcer / Q000188:drug therapy* / Q000191:economics / Q000382:microbiology
chemical_list: D000897:Anti-Ulcer Agents; D011899:Ranitidine; D009853:Omeprazole